Vaccination in the Elderly and IBD

  • Anthony J. Choi
  • Preston Atteberry
  • Dana J. LukinEmail author
Gastroenterology for Geriatric Patients (S Katz and A Afzali, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Gastroenterology for Geriatric Patients


Purpose of review

Significant gaps in knowledge and utilization of vaccinations exist among practitioners providing care for patients with IBD. This review is intended to update the reader on best practices for vaccination within the IBD population with a specific focus on the elderly.

Recent findings

Advances in IBD therapeutics have recently increased the number of immunosuppressive therapies available to practitioners. Differences in mechanisms of action of these medications have led to differential implications pertaining to vaccination strategies. Additionally, new vaccines, including the recombinant zoster vaccine, have recently become available for the use in the IBD population.


Given the prominent role the IBD provider plays in the management of patients with IBD, a clear understanding of best practices is essential. This review provides a framework for the integration of optimal vaccination strategies for practitioners caring for adult and elderly patients with IBD.


Inflammatory bowel disease Vaccination Preventive health maintenance Elderly Crohn’s disease Ulcerative colitis 


Author Contributions

Authored first draft (AC, DJL), critical revisions (all), approved final draft (all).

Compliance with Ethical Standards

Conflict of Interest

Dana Lukin reports grants and personal fees from Abbvie; personal fees from Janssen, Pfizer, Prometheus, Celgene, and Salix; and educational grants from Takeda. Anthony Choi declares that he has no conflict of interest. Preston Atteberry declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently are highlighted as follows: • Of importance •• Of major importance

  1. 1.
    Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2018;390(10114):2769–78.PubMedCrossRefGoogle Scholar
  2. 2.
    Gisbert JP, Chaparro M. Systematic review with meta-analysis: inflammatory bowel disease in the elderly. Aliment Pharmacol Ther. 2014;39(5):459–77.PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Hussain SW, Pardi DS. Inflammatory bowel disease in the elderly. Drugs Aging. 2010;27(8):617–24.PubMedCrossRefGoogle Scholar
  4. 4.
    Loftus EV, Silverstein MD, Sandborn WJ, Tremaine WJ, Harmsen WS, Zinsmeister AR. Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gut. 2000;46(3):336–43.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    • Selby L, Kane S, Wilson J, et al. Receipt of preventive health services by IBD patients is significantly lower than by primary care patients. Inflamm Bowel Dis. 2008;14(2):253–8 This study identified gaps in the receipt of routine preventive care, including vaccinations, within the IBD population.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Selby L, Hoellein A, Wilson JF. Are primary care providers uncomfortable providing routine preventive care for inflammatory bowel disease patients? Dig Dis Sci. 2011;56(3):819–24.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Wasan SK, Coukos JA, Farraye FA. Vaccinating the inflammatory bowel disease patient: deficiencies in gastroenterologists knowledge. Inflamm Bowel Dis. 2011;17(12):2536–40.PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Yeung JH, Goodman KJ, Fedorak RN. Inadequate knowledge of immunization guidelines: a missed opportunity for preventing infection in immunocompromised IBD patients. Inflamm Bowel Dis. 2012;18(1):34–40.PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Castle SC. Clinical relevance of age-related immune dysfunction. Clin Infect Dis. 2000;31(2):578–85.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    • Ciabattini A, Nardini C, Santoro F, Garagnani P, Franceschi C, Medaglini D. Vaccination in the elderly: the challenge of immune changes with aging. Semin Immunol. 2018;40:83–94 This article describes differnences in the immune response to vaccination among elderly patients.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Gecse KB, Lakatos PL. IBD in 2016: biologicals and biosimilars in IBD - the road to personalized treatment. Nat Rev Gastroenterol Hepatol. 2017;14(2):74–6.PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Viget N, Vernier-Massouille G, Salmon-Ceron D, Yazdanpanah Y, Colombel JF. Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut. 2008;57(4):549–58.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    • Kirchgesner J, Lemaitre M, Carrat F, Zureik M, Carbonnel F, Dray-Spira R. Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases. Gastroenterology. 2018;155(2):337–346.e10 Synopsis of infectious risk among patients with IBD. This frames the need for preventive vaccination in this population.Google Scholar
  14. 14.
    Lopez A, Mariette X, Bachelez H, et al. Vaccination recommendations for the adult immunosuppressed patient: a systematic review and comprehensive field synopsis. J Autoimmun. 2017;80:10–27.PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Adult Immunization Schedule by Vaccine and Age Group | CDC [Internet]. [cited 2019 19];Available from:
  16. 16.
    Chow EJ, Davis CT, Abd Elal AI, et al. Update: influenza activity - United States and worldwide, May 20-October 13, 2018. MMWR Morb Mortal Wkly Rep. 2018;67(42):1178–85.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Meites E; Kempe A, Markowitz LE. Use of a 2-dose schedule for human papilloma virus vaccination - updated recommendations of the Advisory Committee on Immunization Practices. MMWR 2016; 65(49);1405–1408PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
  19. 19.
    •• Farraye FA, Melmed GY, Lichtenstein GR, Kane SV. ACG clinical guideline: preventive care in inflammatory bowel disease. Am J Gastroenterol. 2017;112(2):241–58 This important guideline details best practices for preventive care within the IBD patient population with an in-depth description of vaccine recommendations.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):e44–100.PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    Rahier J-F, Papay P, Salleron J, et al. H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy. Gut. 2011;60(4):456–62.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Dotan I, Werner L, Vigodman S, et al. Normal response to vaccines in inflammatory bowel disease patients treated with thiopurines. Inflamm Bowel Dis. 2012;18(2):261–8.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Agarwal N, Ollington K, Kaneshiro M, Frenck R, Melmed GY. Are immunosuppressive medications associated with decreased responses to routine immunizations? A systematic review. Vaccine. 2012;30(8):1413–24.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Loubet P, Verger P, Abitbol V, Peyrin-Biroulet L, Launay O. Pneumococcal and influenza vaccine uptake in adults with inflammatory bowel disease in France: results from a web-based study. Dig Liver Dis. 2018;50(6):563–7.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Melmed GY, Ippoliti AF, Papadakis KA, et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol. 2006;101(8):1834–40.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Malhi G, Rumman A, Thanabalan R, et al. Vaccination in inflammatory bowel disease patients: attitudes, knowledge, and uptake. J Crohns Colitis. 2015;9(6):439–44.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Parker S, Chambers White L, Spangler C, et al. A quality improvement project significantly increased the vaccination rate for immunosuppressed patients with IBD. Inflamm Bowel Dis. 2013;19(9):1809–14.PubMedPubMedCentralGoogle Scholar
  28. 28.
    Reich JS, Miller HL, Wasan SK, et al. Influenza and pneumococcal vaccination rates in patients with inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2015;11(6):396–401.Google Scholar
  29. 29.
    Kasper AK, Pallotta AM, Kovacs CS, Spinner ML. Infectious diseases consult improves vaccination adherence in kidney transplant candidates. Vaccine. 2018;36(34):5112–5.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Gisbert JP, Chaparro M. Vaccination strategies in patients with IBD. Nat Rev Gastroenterol Hepatol. 2013;10(5):277–85.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Long MD, Martin C, Sandler RS, Kappelman MD. Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;37(4):420–9.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Kim DK, Riley LE, Hunter P. Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older - United States, 2018. MMWR Morb Mortal Wkly Rep. 2018;67(5):158–60.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Narula N, Yamamura DLR, Marshall JK. Should my patient with inflammatory bowel disease on immunosuppressive therapy be vaccinated against influenza virus? Can J Gastroenterol. 2010;24(2):121–5.PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Chang JY, Jung S-A, Moon CM, Kim S-E, Jung H-K, Shim K-N. Response to hepatitis B vaccination in patients with inflammatory bowel disease: a prospective observational study in Korea. Intest Res. 2018;16(4):599–608.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    • Pratt PK, David N, Weber HC, et al. Antibody response to hepatitis B virus vaccine is impaired in patients with inflammatory bowel disease on infliximab therapy. Inflamm Bowel Dis. 2018;24(2):380–6 This recent study highlights the potential adverse impact of TNF antagonist therapy on the immunogenicity of the hepatitis B vaccine in the IBD population.PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Gisbert JP, Villagrasa JR, Rodríguez-Nogueiras A, Chaparro M. Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease. Am J Gastroenterol. 2012;107(10):1460–6.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part II: immunization of adults. MMWR Recomm Rep. 2006;55(RR-16):1–33 quiz CE1.Google Scholar
  38. 38.
    Andrade P, Santos-Antunes J, Rodrigues S, Lopes S, Macedo G. Treatment with infliximab or azathioprine negatively impact the efficacy of hepatitis B vaccine in inflammatory bowel disease patients. J Gastroenterol Hepatol. 2015;30(11):1591–5.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Cleveland NK, Rodriquez D, Wichman A, Pan I, Melmed GY, Rubin DT. Many inflammatory bowel disease patients are not immune to measles or pertussis. Dig Dis Sci. 2016;61(10):2972–6.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Caldera F, Misch EA, Saha S, et al. Immunosuppression does not affect antibody concentrations to measles, mumps, and rubella in patients with inflammatory bowel disease. Dig Dis Sci. 2019;64(1):189–95.PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Andrisani G, Frasca D, Romero M, et al. Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: effects of combined therapy with immunosuppressants. J Crohns Colitis. 2013;7(4):301–7.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Gelinck LBS, van der Bijl AE, Beyer WEP, et al. The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination. Ann Rheum Dis. 2008;67(5):713–6.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Hagihara Y, Ohfuji S, Watanabe K, et al. Infliximab and/or immunomodulators inhibit immune responses to trivalent influenza vaccination in adults with inflammatory bowel disease. J Crohns Colitis. 2014;8(3):223–33.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Lu Y, Bousvaros A. Immunizations in children with inflammatory bowel disease treated with immunosuppressive therapy. Gastroenterol Hepatol (N Y). 2014;10(6):355–63.Google Scholar
  45. 45.
    Mamula P, Markowitz JE, Piccoli DA, Klimov A, Cohen L, Baldassano RN. Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5(7):851–6.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    deBruyn JCC, Hilsden R, Fonseca K, et al. Immunogenicity and safety of influenza vaccination in children with inflammatory bowel disease. Inflamm Bowel Dis. 2012;18(1):25–33.PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Cullen G, Bader C, Korzenik JR, Sands BE. Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease. Gut. 2012;61(3):385–91.PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Nguyen DL, Nguyen ET, Bechtold ML. Effect of immunosuppressive therapies for the treatment of inflammatory bowel disease on response to routine vaccinations: a meta-analysis. Dig Dis Sci. 2015;60(8):2446–53.PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    deBruyn J, Fonseca K, Ghosh S, et al. Immunogenicity of influenza vaccine for patients with inflammatory bowel disease on maintenance infliximab therapy: a randomized trial. Inflamm Bowel Dis. 2016;22(3):638–47.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    • Melmed GY. Vaccinations while on thiopurines: some protection is better than none. Am J Gastroenterol. 2012;107(1):141–2 This study demonstrates that despite numerous studies demonstrating a blunted immune response to vaccinations among patients with IBD receiving thiopurine immunosuppression, the diminished immune response is still likely sufficient to provide protection against illness, including with influenza.PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Beaulieu DB, Ananthakrishnan AN, Martin C, Cohen RD, Kane SV, Mahadevan U. Use of biologic therapy by pregnant women with inflammatory bowel disease does not affect infant response to vaccines. Clin Gastroenterol Hepatol. 2018;16(1):99–105.PubMedCrossRefPubMedCentralGoogle Scholar
  52. 52.
    Julsgaard M, Christensen LA, Gibson PR, et al. Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection. Gastroenterology. 2016;151(1):110–9.PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53.
    Brogan MD, Shanahan F, Oliver M, Stevens RH, Targan SR. Defective memory B cell formation in patients with inflammatory bowel disease following tetanus toxoid booster immunization. J Clin Lab Immunol. 1987;24(2):69–74.PubMedPubMedCentralGoogle Scholar
  54. 54.
    Nielsen HJ, Mortensen T, Holten-Andersen M, Brünner N, Sørensen S, Rask-Madsen J. Increased levels of specific leukocyte- and platelet-derived substances during normal anti-tetanus antibody synthesis in patients with inactive Crohn disease. Scand J Gastroenterol. 2001;36(3):265–9.PubMedCrossRefPubMedCentralGoogle Scholar
  55. 55.
    Rüddel J, Schleenvoigt BT, Schüler E, Schmidt C, Pletz MW, Stallmach A. Yellow fever vaccination during treatment with infliximab in a patient with ulcerative colitis: a case report. Z Gastroenterol. 2016;54(9):1081–4.PubMedCrossRefPubMedCentralGoogle Scholar
  56. 56.
    Ekenberg C, Friis-Møller N, Ulstrup T, Aalykke C. Inadvertent yellow fever vaccination of a patient with Crohn’s disease treated with infliximab and methotrexate. BMJ Case Rep. 2016;2016.Google Scholar
  57. 57.
    Toruner M, Loftus EV, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134(4):929–36.PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Osterman MT, Haynes K, Delzell E, et al. Effectiveness and safety of immunomodulators with anti-tumor necrosis factor therapy in Crohn’s disease. Clin Gastroenterol Hepatol. 2015;13(7):1293–1301.e5 quiz e70, e72.PubMedCentralCrossRefGoogle Scholar
  59. 59.
    • Khan N, Vallarino C, Lissoos T, Darr U, Luo M. Risk of infection and types of infection among elderly patients with inflammatory bowel disease: a retrospective database analysis. Inflamm Bowel Dis 2019. This large retrospective Truven database study identified an increased risk of pneumonia and sepsis among elderly patients with IBD as compared to those aged 18-64.Google Scholar
  60. 60.
    Ananthakrishnan AN, McGinley EL. Infection-related hospitalizations are associated with increased mortality in patients with inflammatory bowel diseases. J Crohns Colitis. 2013;7(2):107–12.PubMedCrossRefPubMedCentralGoogle Scholar
  61. 61.
    • Kantsø B, Simonsen J, Hoffmann S, Valentiner-Branth P, Petersen AM, Jess T. Inflammatory bowel disease patients are at increased risk of invasive pneumococcal disease: a nationwide Danish cohort study 1977-2013. Am J Gastroenterol. 2015;110(11):1582–7 This study highlights the increased risk of invasive pneumococcal infection within patients with IBD and therefore the importance of proactive immunization in the immunosuppressed population.PubMedCrossRefPubMedCentralGoogle Scholar
  62. 62.
    Melmed GY, Agarwal N, Frenck RW, et al. Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease. Am J Gastroenterol. 2010;105(1):148–54.PubMedCrossRefPubMedCentralGoogle Scholar
  63. 63.
    Fiorino G, Peyrin-Biroulet L, Naccarato P, et al. Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis. 2012;18(6):1042–7.PubMedCrossRefPubMedCentralGoogle Scholar
  64. 64.
    van Aalst M, Garrido HMG, van der Leun J, et al. Immunogenicity of the currently recommended pneumococcal vaccination schedule in patients with inflammatory bowel disease. Clin Infect Dis 2019;Google Scholar
  65. 65.
    Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn’s disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009;7(8):874–81.PubMedPubMedCentralCrossRefGoogle Scholar
  66. 66.
    Schmader K. Herpes zoster in older adults. Clin Infect Dis. 2001;32(10):1481–6.PubMedCrossRefPubMedCentralGoogle Scholar
  67. 67.
    Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82(11):1341–9.PubMedCrossRefPubMedCentralGoogle Scholar
  68. 68.
    Khan N, Patel D, Trivedi C, et al. Overall and comparative risk of herpes zoster with pharmacotherapy for inflammatory bowel diseases: a nationwide cohort study. Clin Gastroenterol Hepatol. 2018;16(12):1919–1927.e3.PubMedCrossRefPubMedCentralGoogle Scholar
  69. 69.
    Nugent Z, Singh H, Targownik LE, Bernstein CN. Herpes zoster infection and herpes zoster vaccination in a population-based sample of persons with IBD: is there still an unmet need? Inflamm Bowel Dis. 2019;25(3):532–40.PubMedCrossRefPubMedCentralGoogle Scholar
  70. 70.
    Zhang J, Xie F, Delzell E, et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA. 2012;308(1):43–9.PubMedPubMedCentralCrossRefGoogle Scholar
  71. 71.
    Winthrop KL, Baddley JW, Chen L, et al. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA. 2013;309(9):887–95.PubMedPubMedCentralCrossRefGoogle Scholar
  72. 72.
    Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699–710.PubMedCrossRefPubMedCentralGoogle Scholar
  73. 73.
    Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369(8):711–21.PubMedCrossRefGoogle Scholar
  74. 74.
    Meserve J, Aniwan S, Koliani-Pace JL, et al. Retrospective analysis of safety of vedolizumab in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2018; 17(8):1533-1540.e2PubMedCrossRefPubMedCentralGoogle Scholar
  75. 75.
    Schreiber S, Dignass A, Peyrin-Biroulet L, et al. Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease. J Gastroenterol. 2018;53(9):1048–64.PubMedPubMedCentralCrossRefGoogle Scholar
  76. 76.
    Lukin DJ, Weiss A, Aniwan S, et al. 277 - Comparative safety profile of vedolizumab and tumor necrosis factor-antagonist therapy for inflammatory bowel disease: a multicenter consortium propensity score-matched analysis. Gastroenterology. 2018;154(6):S-68.CrossRefGoogle Scholar
  77. 77.
    Schreiber S, Peyrin-Biroulet L, Loftus EV, et al. OP34 VARSITY: a double-blind, double-dummy, randomised, controlled trial of vedolizumab versus adalimumab in patients with active ulcerative colitis. J Crohn's Colitis. 2019;13(Supplement_1):S612–3.CrossRefGoogle Scholar
  78. 78.
    Adar T, Faleck D, Sasidharan S, et al. Comparative safety and effectiveness of tumor necrosis factor α antagonists and vedolizumab in elderly IBD patients: a multicentre study. Aliment Pharmacol Ther. 2019;49(7):873–9.PubMedCrossRefPubMedCentralGoogle Scholar
  79. 79.
    Navaneethan U, Edminister T, Zhu X, Kommaraju K, Glover S. Vedolizumab is safe and effective in elderly patients with inflammatory bowel disease. Inflamm Bowel Dis. 2017;23(4):E17.PubMedCrossRefPubMedCentralGoogle Scholar
  80. 80.
    Harrington JE, Hamilton RE, Wasan SK, Farraye FA, Ganley-Leal L. Immunogenicity of the influenza vaccine in IBD patients treated with vedolizumab. American Journal of Gastroenterology 2018;113(Supplement):S407–8.CrossRefGoogle Scholar
  81. 81.
    • Wyant T, Leach T, Sankoh S, et al. Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results. Gut. 2015;64(1):77–83. Vedolizumab as a gut-selective lymphocyte trafficking inhibitor which does not cause systemic immunosuppression. This study shows that immunogenicity to oral antigens but not parenterally administered antigens is impaired by vedolizumab. The “gut-selectivity” leads to preserved systemic immune function, leading to the recommendation that live parenteral vaccines will not place patients at risk for infection.PubMedCrossRefPubMedCentralGoogle Scholar
  82. 82.
    UC A. ENTYVIO (vedolizumab) for injection, for intravenous use [Internet]. [cited 2019 28];Available from: Accessed June 30, 2019.
  83. 83.
    SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) Suspension for Intramuscular Injection [Internet]. [cited 2019 26];Available from: Accessed June 30, 2019.
  84. 84.
    • Reich J, Pei-Hsuan L, Zahorian T, Noronha A, Wasan SK, Farraye FA. P2231 - use of recombinant zoster vaccine (RZV-Shingrix) in patients with inflammatory bowel disease. ACG 2018 Annual Scientific Meeting Abastracts 2018 ;This is the first report of the use of the recombinant zoster vaccine among patients with IBD. While the size was limited, immunogenicity appears comparable with the general population.Google Scholar
  85. 85.
    Winthrop KL, Melmed GY, Vermeire S, et al. Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib. Inflamm Bowel Dis. 2018;24(10):2258–65.PubMedPubMedCentralCrossRefGoogle Scholar
  86. 86.
    Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376(18):1723–36.PubMedCrossRefPubMedCentralGoogle Scholar
  87. 87.
    Sandborn WJ, Panés J, D’Haens GR, et al. Safety of tofacitinib for treatment of ulcerative colitis, based on 4.4 years of data from global clinical trials. Clin Gastroenterol Hepatol. 2018;17(8):1541–50.PubMedCrossRefPubMedCentralGoogle Scholar
  88. 88.
    IBD Checklist for Monitoring & Prevention [Internet]. [cited 2019 Apr 19];Available from: Accessed June 30, 2019.
  89. 89.
    IBD and Keeping up with Immunization [Internet]. [cited 2019 18];Available from: Accessed June 30, 2019.

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Anthony J. Choi
    • 1
  • Preston Atteberry
    • 1
  • Dana J. Lukin
    • 1
    • 2
    Email author
  1. 1.Division of Gastroenterology and HepatologyNew York Presbyterian Hospital-Weill Cornell Medical CollegeNew YorkUSA
  2. 2.Jill Roberts Center for IBDNew York Presbyterian Hospital-Weill Cornell Medical CollegeNew YorkUSA

Personalised recommendations